Dosage and Administration of Anti-C5 Antibodies for the Treatment of Myasthenia Gravis

JP2024526742A5Pending Publication Date: 2025-07-23ALEXION PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024501754
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-05
Filing Date
2022-07-14
Publication Date
2025-07-23

AI Technical Summary

Technical Problem

Current treatments for myasthenia gravis, particularly generalized myasthenia gravis (gMG), are not effective for all patients, leading to severe morbidity and limited treatment options, with uncontrolled terminal complement activation contributing to neuromuscular dysfunction.

Method used

Administration of anti-C5 antibodies, such as ravulizumab, to inhibit complement activation and reduce inflammation at the neuromuscular junction, following a specific clinical administration regimen.

Benefits of technology

Significant improvement in myasthenia gravis activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) scores, with clinically meaningful reductions observed after 26 weeks of treatment, indicating improved neuromuscular function and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000098_0000
    Figure 00000098_0000
  • Figure 00000098_0001
    Figure 00000098_0001
  • Figure 00000098_0002
    Figure 00000098_0002
Patent Text Reader

Abstract

Methods for the clinical treatment of myasthenia gravis (MG) using anti-C5 antibodies or antigen-binding fragments thereof are provided.
Need to check novelty before this filing date? Find Prior Art